266P MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01)

Autor:	A. Hennequin, Matteo Simonelli, D. Laurent, Hans Wildiers, Santiago Escrivá-de-Romaní, S Waters, Andrea Pellacani, G. Del Conte, Giuseppe Curigliano, M. Ruiz Borrego, François Duhoux, B. Doger De Speville Uribe, F. Amair-Pinedo, Sacha J Howell, Diego Tosi, M. Palleschi, B. Jimenez-Rodriguez, P.G. Aftimos, M.J. Piccart, H-T. Arkenau
Rok vydání:	2021
Předmět:	Breast cancer Oncology Fulvestrant business.industry Trastuzumab Mutant Cancer research Medicine Hematology business medicine.disease PI3K/AKT/mTOR pathway medicine.drug
Zdroj:	Annals of Oncology. 32:S478-S479
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2021.08.549
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::bf8582873638353bb3b52150b2b496b6 https://doi.org/10.1016/j.annonc.2021.08.549 Zobrazit plný text záznamu